Video 2020: Mark Shikowitz, MD, MBA

Press Release: Dr. Mark Jay Shikowitz

Get to know Otolaryngologist Dr. Mark J. Shikowitz, who serves patients in New Hyde Park, New York. 

Dr. Shikowitz is a board-certified otolaryngologist who sees patients for a variety of surgical issues associated with the ear, norse & throat, as well as the head and neck. He also takes a special interest in pediatric otolaryngology, and treats adults and adolescents alike. Dr. Shikowitz holds several titles, including Director of The Zucker Sinus Center of Otolaryngology and Communicative Disorders at Long Island Jewish Medical Center and Vice Chairman of Otolaryngology and Communicative Disorders at Long Island Jewish Medical Center, as well as Vice Chairman of Otolaryngology and Communicative Disorders at North Shore University Hospital. Long Island Jewish Medical Center is one of the cornerstones of Northwell Health, providing the full spectrum of clinical healthcare services for patients of all ages. North Shore University Hospital is also a part of Northwell Health, offering care in all medical and surgical specialties, including cardiovascular services, cancer care, orthopedics, maternal-fetal medicine, and women’s health services.

FindATopDoc Profile: Mark Shikowitz, MD, MBA

Mark Shikowitz, MD, MBA, started on his professional journey in 1981 when he obtained his Medical Degree from the The University of Dominica School of Medicine in Roseau, Dominica. He continued to expand his knowledge with his internship in General Surgery at Maimonides Medical Center in Brooklyn, New York, his residency in Otolaryngology at Long Island Jewish Medical Center and his residency in head and neck surgery at New Hyde Park. Dr. Mark Shikowitz is also board certified in otolaryngology, facial cosmetic surgery, and head and neck surgery. Dr. Mark Shikowitz also secured memberships with several respected societies and groups pertaining to his profession, including the American Medical Association, the New York Academy of Sciences, the American Academy of Otolaryngology, the Society for Ear, Nose and Throat Advances in Children, the Long Island Society of Otolaryngology of Head and Neck Surgery, the Association for Research in Otolaryngology, and the American Broncho-Esophagological Association. He attributes his success to his hard work and innovative surgery and procedures while he is actively involved in medical missions around the world. For more information about Dr. Mark Shikowitz, please visit https://www.findatopdoc.com/doctor/8125581-Mark-Shikowitz-Ear-Nose-and-Throat-Doctor-ENT.

Mark Shikowitz, MD

Mark Shikowitz, MD, MBA, is a leading expert in otolaryngology with more than three decades of practice in his field. In his current capacity as Otolaryngologist with Northwell HealthSystem, which he joined in 1986, he reveals extraordinary expertise in sinus surgery, facial cosmetic surgery, head and neck surgery, pituitary tumor surgery, balloon sinuplasty, and endoscopic skull based surgery. Dr. Shikowitz is the Director of the The Zucker Sinus Center of Otolaryngology – Head and Neck Surgery at Long Island Jewish Medical Center and Vice Chairman of Otolaryngology – Head and Neck Surgery at Long Island Jewish Medical Center and North Shore University Hospital. To complement his clinical functions, Dr. Mark Shikowitz is also a Professor of Otolaryngology at Donald and Barbara Zucker School of Medicine at Hofstra/Northwell. With his work revered around the globe, he is also actively involved in speaking engagements in Australia and Europe, where he travels annually to lecture on sinus surgery at Bristol University in England. Furthermore, Dr. Mark Shikowitz is the author of “Speech and swallowing rehabilitation following devastating caustic ingestion: techniques and indicators for success”. In addition to his coursework, Dr. Mark Shikowitz also completed post-doctoral research on the human papillomavirus and subsequent tumors at the National Institute of Health in Maryland. For more information about Dr. Mark Shikowitz, please visit https://www.northwell.edu/find-care/find-a-doctor/otolaryngology/dr-mark-jay-shikowitz-md-mba-11315410.

 

My Video

Researchers ID potential prognostic marker for recurrence of head & neck squamous cell carcinoma

Molecular profiling may be useful for early diagnosis and treatment decisions, according to study published in the American Journal of Pathology

A new study provides the first evidence that the mediator complex subunit 15 (MED15) may play a crucial role in the pathophysiology of head and neck squamous cell carcinoma (HNSCC). MED15 overexpression was found to be associated with higher mortality rates in HNSCC patients with cancer recurrence, particularly in oral cavity/oropharyngeal tumors, according to the study published in the American Journal of Pathology. MED15 overexpression was also associated with heavy alcohol consumption, which is an HNSCC risk factor.HNSCC is the sixth most common cancer worldwide and has a high rate of recurrence and early metastatic disease, resulting in approximately 350,000 deaths each year. “Our findings suggest that MED15 may serve as a prognostic marker for HNSCC recurrence and as a therapeutic target in HNSCC patients suffering from recurrences,” said lead investigator Sven Perner, MD, PhD, of the Department of Prostate Cancer Research, Institute of Pathology, and the Department of Otorhinolaryngology at the University Hospital of Bonn (Germany).

Read the rest of the article at http://www.medicalnewstoday.com/releases/291264.php.

Morphine after tonsillectomy ‘potentially life-threatening’ for children

Painkilling medication is usually prescribed following most forms of surgery. However, the use of morphine to treat the post-operative pain of children having their tonsils removed could lead to potentially life-threatening respiratory problems, according to the findings of a new study.

The effects of morphine were so severe that the study’s Drug Safety Monitoring Board halted the study period early. In contrast, the study showed that ibuprofen could be used safely and effectively as an alternative.”These results should prompt clinicians to re-evaluate their post-tonsillectomy pain treatment regimen. Due to the unpredictable respiratory side-effects of morphine, its use as a first-line treatment with current dosage ranges should be discontinued for outpatient tonsillectomy,” says study co-author Dr. Doron Sommer.

Read the rest of the article at http://www.medicalnewstoday.com/articles/288534.php.

HPV vaccine highly effective against multiple cancer-causing strains

According to a multinational clinical trial involving nearly 20,000 young women, the human papilloma virus vaccine, Cervarix, not only has the potential to prevent cervical cancer, but was effective against other common cancer-causing human papillomaviruses, aside from just the two HPV types, 16 and 18, which are responsible for about 70 percent of all cases. That effectiveness endured for the study’s entire follow-up, of up to four years. The research was published in Clinical and Vaccine Immunology, a journal of the American Society for Microbiology.”The study confirms that targeting young adolescent girls before sexual debut for prophylactic HPV vaccination has a substantial impact on the incidence of high grade cervical abnormalities,” said corresponding author, Dan Apter, Director, The Sexual Health Clinic, Family Federation of Finland, Helsinki.The vaccine was extremely effective in young women who had never been infected with HPV. It protected nearly all from HPV-16 and -18, and protected 50-100 percent against different grades of precancerous transformation of cervical cells caused by other strains of HPV, including up to 100 percent of those with the immediate precursor grade to cancer. The women were followed for up to four years post-vaccination.

Read the rest of the article at http://www.medicalnewstoday.com/releases/289503.php.

Glioblastoma: Study ties 3 genes to radiation resistance in recurrent tumors

A new study identifies three genes that together enable a lethal form of brain cancer to recur and progress after radiation therapy.The findings might lead to new therapies that target cancer stem cells, say researchers at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James), who led the study.The work focused on the brain cancer glioblastoma multiforme (GBM). It investigated a subset of cancer cells within those tumors that behave like stem cells and that sometimes survive radiation therapy. To understand how those cancer stem-like cells survive irradiation, the researchers examined the cancer-related gene EZH2, which is unregulated in GBM and other cancers.They discovered that in GBM stem-like cells – but not in other tumor cancer cells or in healthy body cells – EZH2 is regulated/controlled by a gene called MELK in combination with a second gene, FOXM1. The interaction of the three genes helps the cells survive therapy.

Read the rest of the article at http://www.medicalnewstoday.com/releases/288940.php.

Using 3-D printing, MakerBot and Feinstein Institute repair tracheal damage

Results are showcased at 51st Annual Meeting of The Society of Thoracic Surgeons

Investigators at The Feinstein Institute for Medical Research have made a medical breakthrough using 3D printing on a MakerBot® Replicator® 2X Experimental 3D Printer to create cartilage designed for tracheal repair or replacement. The results were reported today at the 51st Annual Meeting of The Society of Thoracic Surgeons in San Diego, in a presentation by Todd Goldstein, an investigator at the Feinstein Institute, part of the North Shore-LIJ Health System. This is a first for medical research where regular MakerBot PLA Filament was used to 3D print a custom tracheal scaffolding, which was combined with living cells to create a tracheal segment. For more information read here  http://www.medicalnewstoday.com/releases/288613.php.